Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

NORCROSS, Ga., March 29, 2013 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2012. These results are included in the Company's Quarterly Report on Form 10-K, which has been filed with the SEC.

"It was a year of great progress for our Company," said Peter G. Traber , M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. "We completed a significant fundraising and our stock was listed on the NASDAQ Capital Market earlier in the year, we relocated our headquarters to Norcross, Georgia during the fourth quarter, and we made significant advances developing our fibrosis program. We have continued this progress into 2013, having submitted an IND for GR-MD-02 in January and received the FDA's ok that we could proceed with a Phase 1 clinical trial. We expect to initiate a Phase 1 clinical trial of GR-MD-02 during the second quarter of 2013 in patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis and have engaged CTI Clinical Trial Services to provide services related to this trial. The novel mechanism of action of GR-MD-02, in combination with compelling preclinical data, gives us great hope that this compound may ultimately meet the needs of patients with this deadly disease that currently has no approved therapeutic options."

At December 31, 2012, the Company had $9.4 million of non-restricted cash and cash equivalents available to fund future operations.  The Company believes that with the funds on hand at December 31, 2012, there is sufficient cash to fund core operations and planned research and development through the first quarter of 2014.

For the fourth quarter of 2012, the Company reported a net lo
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  Therapath Neuropathology ( www.Therapath.com ... partnerships with VA and Military Medical centers both ... Density (ENFD) and Sweat Gland Nerve Fiber Density ... ( https://therapath.com/skin ). Demonstration of ... (ENFD) on punch skin biopsy is a highly ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company, is pleased to announce that the ... (RCI-02) have been locked.  Prototypes for industrial and ... for an application for CE mark clearance to ... in 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 ...
(Date:7/29/2015)... ... July 29, 2015 , ... Available in select spas and ... a nighttime-specific product that targets fat cells for extreme contouring action. During sleep ... fat cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks down ...
(Date:7/29/2015)... ... July 29, 2015 , ... Nearly everyone has heard of the potential of ... that a rich source of these cells is teeth—baby teeth that come loose during ... be pulled to make room for braces. These potent stem cells exist in ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2
... in a hexagonal, chicken wire structure holds great ... conductive, graphene may one day replace conventional silicon microchips, ... In addition to potential applications in integrated circuits, solar ... material has attracted the attention of physicists for its ...
... Inc. (NYSE Amex: NBS ), an international biopharmaceutical company ... will present on a panel at the 31st Annual Cowen Group ... March 7, 2011 at 1 PM and Dr. Robin Smith, the ... at 10:15 AM. The Conference will be held at the Boston ...
... Corporation (Nasdaq: VOLC ), a leading developer ... enhance the diagnosis and treatment of coronary and peripheral ... market the Eagle Eye® Platinum digital IVUS catheter in ... PCI Live Demonstration Course in Kurashiki, which starts on ...
Cached Biology Technology:Probing atomic chicken wire 2Probing atomic chicken wire 3Probing atomic chicken wire 4NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8 2NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8 3Volcano Announces the Introduction of the Eagle Eye® Platinum Digital IVUS Catheter at the 20th PCI Live Demonstration Course in Kurashiki 2Volcano Announces the Introduction of the Eagle Eye® Platinum Digital IVUS Catheter at the 20th PCI Live Demonstration Course in Kurashiki 3
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
(Date:6/29/2015)... DUBLIN , June 24, 2015 ... the addition of the "Latin America Biomedical Sensors ... to their offering. The Latin America Biomedical ... at a CAGR of 2.04% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2
... from the University of Hawaii, the Wildlife Conservation ... and Projecto Meros do Brazil discovered a new species ... in length and can weigh nearly 1,000 pounds. This ... reefs of the Eastern Pacific Ocean. Was ...
... and MobileCampus(TM) Wireless Data Communications Link School ... Security, Administration and ... (OTC Bulletin Board: BKYI), a leader in finger-based biometric,identification ... MobileSRO(TM) and MobileCampus(TM), silent, secure,emergency alert and management solutions ...
... Investor Spark Capital Leads Round with Additional Funding by ... Including Lockheed Martin, GE Security, Baker ... Clear(R), the fast pass for airport,security, has secured ... Capital, this round also includes a second investor Syncom ...
Cached Biology News:Genetics reveals big fish that almost got away 2BIO-key(R) Announces Emergency Alert and Management Solutions for Schools and Campuses 2BIO-key(R) Announces Emergency Alert and Management Solutions for Schools and Campuses 3Clear(R) Secures $44.4 Million in Venture Funding 2Clear(R) Secures $44.4 Million in Venture Funding 3
... Microarray Kit (V2), 22K is useful for investigating ... Each microarray contains content derived from the ATH1 ... Research (TIGR) and represents 21,500 genes. ... x 3? glass slides each containing an identical ...
... projects require screening through a huge ... relevant data from normal biologic diversity. ... now available to help better manage ... flood inherent to biomarker discovery. The ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... Speed Shaker ,Product Information ... is a high quality, general purpose shaker with ... the other models in the line, the Orbit ... control panel. Electronic controls are utilized for setting ...
Biology Products: